UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
(
(Registrant’s telephone number, include area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2 below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: |
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02. Results of Operations and Financial Condition.
On March 6, 2023, Immuneering Corporation (the “Company”) announced its financial results for the quarter and full-year ended December 31, 2022 and provided business updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Current Report”).
The information in this Item 2.02 of this Current Report, including Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.
Item 7.01. Regulation FD Disclosure.
On March 6, 2023, the Company posted an updated corporate slide presentation in the “For Investors” portion of its website at www.immuneering.com. A copy of the slide presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K.
The information in this Item 7.01 of this Current Report, including Exhibit 99.2, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly provided by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
The following exhibits relate to Items 2.02 and 7.01, which shall be deemed to be furnished, and not filed:
Exhibit | ||
No. |
| Description |
99.1 | ||
99.2 | Immuneering Corporation Corporate Slide Presentation as of March 6, 2023 | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IMMUNEERING CORPORATION | ||
Date: March 6, 2023 | By: | /s/ Benjamin J. Zeskind |
Name: Benjamin J. Zeskind, Ph.D. | ||
Title: Co-Founder, President, Chief Executive Officer and Director (Principal Executive Officer) | ||
Exhibit 99.1
Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
First patient dosed in Phase 1/2a clinical trial of IMM-1-104 in advanced solid tumors with any RAS mutation
Provides debut guidance for IMM-1-104 program: initial Phase 1 PK and safety data expected in mid-2023, initial Phase 1 PD modeling and additional PK and safety data expected in 2H 2023, recommended phase 2 dose and additional safety data expected in mid-2024
Continued progress in oncology pipeline - on track to file IND for IMM-6-415 in Q4 2023
Cash runway extended into Q4 2024; sharpened focus on oncology pipeline and suspension of discovery-stage neuroscience programs
Conference call and webcast today at 4:30 p.m. ET.
CAMBRIDGE, Mass., March 6, 2023 -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided recent business updates.
“2022 was a year of important progress towards our goal of creating impactful new medicines for cancer patients,” said Ben Zeskind, Ph.D., MBA, Co-founder, and Chief Executive Officer of Immuneering. “IMM-1-104, the first and only MAPK pathway inhibitor with the potential for universal-RAS activity, entered the clinic as we dosed the first patient in our Phase 1/2a clinical trial in November, enrolling patients with advanced solid tumors harboring RAS mutations. With a unique and counterintuitive mechanism of deep cyclic inhibition, IMM-1-104 was designed to limit toxicity and maximize therapeutic activity by selectively targeting cancer cells based on their increased need for sustained MAPK pathway signaling, while sparing healthy cells which are less dependent on continuous pathway signaling. IMM-1-104 is being evaluated as an oral, once-daily monotherapy. Our goal is to provide newer and better treatment options for patients with tumors driven by any mutation in KRAS, NRAS, or HRAS.”
Dr. Zeskind continued: “We are very pleased with the progress of our trial, which enables us today to provide debut guidance on when investors can expect to see initial data from our ongoing IMM-1-104 Phase 1/2a clinical trial. Currently, we plan to share (1) initial Phase 1 pharmacokinetic (PK)
and safety data in mid-2023, followed by (2) initial Phase 1 pharmacodynamic (PD) modeling and additional PK and safety data in the second half of 2023 and (3) the announcement of a recommended Phase 2 dose and additional safety data in mid-2024. We also plan to provide additional trial updates on a periodic basis. Because observing a unique PK profile in humans is a fundamental aspect of our counterintuitive deep cyclic inhibition mechanism, we believe these initial readouts could provide particularly impactful early validation for our approach and the potential universal-RAS activity of IMM-1-104. With our clinical trial rapidly advancing and continued progress accelerating IMM-6-415 toward an IND filing later this year, we have also taken the opportunity to sharpen our focus exclusively to oncology, by suspending our neuroscience programs. This change as well as other non-core adjustments extend our projected cash runway by an additional quarter, into Q4 2024.”
Corporate Highlights
| ● | Preclinical data on lead program IMM-1-104 presented at American Association for Cancer Research (AACR) special conference targeting RAS: In March 2023, Immuneering presented preclinical data in a poster titled, “Pan-RAS IMM-1-104 activity in humanized 3D tumor models is independent of specific amino acid substitution.” IMM-1-104 demonstrated response across RAS mutant preclinical models regardless of mutation position or amino acid substitution, suggesting potential relevance to a broad universal-RAS-driven patient population. |
| ● | Cash runway extended into Q4 2024 with sharpened focus on oncology pipeline: In March 2023, Immuneering announced the company would sharpen its focus exclusively to its oncology pipeline, suspending its discovery-stage neuroscience programs. With this change, and other non-core adjustments, based on cash, cash equivalents and marketable securities and current operating plans, the company now expects its cash runway to extend into the fourth quarter of 2024. |
| ● | First patient dosed in Phase 1/2a Clinical Trial of IMM-1-104 in advanced solid tumors with RAS mutations: In September 2022, Immuneering received FDA clearance of the IND application for IMM-1-104 and in November 2022, commenced dosing in a Phase 1/2a open-label study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of IMM-1-104 as an oral, once-daily monotherapy in patients with advanced RAS mutant solid tumors. To the company’s knowledge, this is the first and only clinical trial for which patients with any mutation in KRAS, NRAS, or HRAS are eligible to be screened for other enrollment criteria. The Phase 1 portion of the study, which is being conducted at five clinical sites in the United States, includes a dose escalation phase and dose evaluation phase in order to establish an optimized Recommended Phase 2 Dose (RP2D) candidate. Subject to Phase 1 results, the Company currently expects to conduct a |
| Phase 2a dose expansion phase in order to assess the safety and efficacy of IMM-1-104 at the RP2D in RAS mutated pancreatic, melanoma, lung, and colorectal cancers. The Company is currently in the dose escalation phase of the trial. |
| ● | Preclinical data on its second program IMM-6-415 presented at the 37th Annual Meeting of SITC: In November 2022, Immuneering presented preclinical data in a presentation titled, “Cyclic disruption of the mitogen-activated protein kinase (MAPK) pathway by the Dual MEK inhibitor, IMM-6-415, enhances PD1 and CTLA4 checkpoint blockade in RAS mutant tumors.” IMM-6-415 exhibited preclinical activity as a single-agent in RAF and RAS mutant tumor models, as well as enhanced activity in combination with checkpoint inhibitors (CPIs) in RAS-mutant colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) models driven by diverse MAPK pathway mutations. |
| ● | Chief People Officer appointed: In October 2022, the company announced the appointment of Leah R. Neufeld to the newly created Chief People Officer position. Ms. Neufeld brings decades of experience in life sciences as well as human resources and will join the senior leadership team in continuing to make the company a great place for the all-star team of Immuneers to work and grow, while also helping to add new talent as the company advances a robust pipeline of novel product candidates. |
| ● | Preclinical data presented at ASCO 2022 Annual Meeting highlighting pan-KRAS/NRAS activity of IMM-1-104: In May 2022, Immuneering presented two preclinical abstracts. The first abstract, titled “Head-to-head comparison of the dual-MEK inhibitor IMM-1-104 versus sotorasib or adagrasib in KRAS mutant pancreatic tumors,” demonstrated a lack of Tumor Growth Inhibition (TGI) by sotorasib and adagrasib in KRAS-G12V mutant Capan-2 PDAC tumors. In contrast, IMM-1-104 observed TGIs of 49-84% across all doses and schedules tested. Consistent with other IMM-1-104 in vivo studies, median body weight loss was no more than 3-5% at top doses. The second abstract titled “Translational modeling for patients with RAS mutant tumors: Profiling the dual-MEK inhibitor IMM-1-104 in a humanized 3D assay,” found KRAS mutant pancreatic cancer and NRAS mutant melanoma were the most broadly sensitive patient-aligned models in the 3D-tumor growth assay and are expected to be included among the target indications planned for the Phase 2a portion of Immuneering’s ongoing Phase 1/2a clinical trial. |
Near-Term Milestone Expectations
IMM-1-104
| ● | Initial Phase 1 PK and safety data expected in mid-2023 |
| ● | Initial Phase 1 PD modeling data and additional PK and safety data expected in the second half of 2023 |
| ● | Recommended Phase 2 dose and additional safety data expected in mid-2024 |
| ● | Additional trial updates expected on a periodic basis |
IMM-6-415
| ● | IND filing expected in the fourth quarter of 2023 |
Fourth Quarter and Full Year 2022 Financial Highlights
| ● | Cash Position: Cash, cash equivalents and marketable securities as of December 31, 2022 were $105.5 million, compared with $150.2 million as of December 31, 2021. |
| ● | Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2022 were $9.9 million compared with $7.9 million for the fourth quarter of 2021. Full year 2022 R&D expenses were $36.3 million compared to $26.5 million for full year 2021. The increase in R&D expenses from both periods of 2021 was primarily attributable to higher clinical costs related to the company’s lead program and increased personnel to support ongoing research and development activities. |
| ● | General and Administrative (G&A) Expenses: G&A expenses for the fourth quarter of 2022 were $4.1 million compared with $3.1 million for the same period of 2021. Full year 2022 G&A expenses were $15.6 million compared to $8.3 million for full year 2021. The increase in G&A expenses for both periods of 2022 was primarily attributable to an increase in headcount in the company’s general and administrative functions to support the business, and costs related to operating as a public company. |
| ● | Net Loss: Net loss attributable to common stockholders was $13.2 million, or $0.50 per share, for the quarter ended December 31, 2022, compared to $10.8 million, or $0.42 per share, for the quarter ended December 31, 2021. Net loss attributable to common stockholders for full year 2022 was $50.5 million, or $1.91 per share compared to $33.5 million, or $2.46 per share, for full year 2021. |
2023 Financial Guidance
| ● | Based on cash, cash equivalents and marketable securities, as of December 31, 2022, and current operating plans, the company expects its cash runway to extend into the fourth quarter of 2024. |
Conference Call
Immuneering will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on March 6, 2023, to discuss the results and provide a business and pipeline update. To access the call by phone, please use this registration link, and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. After the live webcast, the event will be archived for 90 days in the Investor Relations section of Immuneering’s website at Events & Presentations.
About Immuneering Corporation
Immuneering is a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The company aims to achieve universal activity through deep cyclic inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate, IMM-1-104, is in a Phase 1/2a study in patients with advanced solid tumors harboring RAS mutations. The company’s development pipeline also includes IMM-6-415, our universal-MAPK inhibitor, as well as several early-stage programs. For more information, please visit www.immuneering.com.
Forward-Looking Statements
This press release includes certain disclosures that contain "forward-looking statements," including, without limitation, statements regarding Immuneering’s expectations regarding the sufficiency of Immuneering’s cash, cash equivalents and marketable securities, current operating plans and cash runway, the treatment potential of IMM-1-104 and IMM-6-415, including estimates of the patient population that may ultimately benefit from treatment, statements regarding the design, enrollment and conduct of the Phase 1/2a clinical trial for IMM-1-104, the timing of initial Phase 1 PK and safety data, initial PD modeling data and additional PK and safety data, additional trial updates, recommended phase 2 dose and additional safety data, the ability of initial readouts to validate the company’s therapeutic approach, the timing of submission of the IND for IMM-6-415, and
Immuneering’s ability to advance its pipeline and further diversify its portfolio and make progress towards its longstanding goal of creating better medicines for cancer patients. Forward-looking statements are based on Immuneering’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including target discovery, target validation, lead compound identification, lead compound optimization, preclinical studies and clinical trials. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in Immuneering’s most recent Form 10-K filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Immuneering undertakes no duty to update such information except as required under applicable law.
Media Contact:
Gina Nugent
Nugent Communications
617-460-3579
gina@nugentcommunications.com
Investor Contact:
Laurence Watts
Gilmartin Group
619-916-7620
laurence@gilmartinir.com
IMMUNEERING CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
| | Three Months Ended December 31 | | Twelve Months Ended December 31 | ||||||||
|
| 2022 |
| 2021 | | 2022 |
| 2021 | ||||
| | | | | | | | | | | | |
Revenue | | $ | 456 | | $ | 189,591 | | $ | 316,952 | | $ | 2,079,961 |
Cost of revenue | |
| — | |
| 206,221 | |
| 158,122 | |
| 1,153,073 |
| | | | | | | | | | | | |
Gross profit | |
| 456 | |
| (16,630) | |
| 158,830 | |
| 926,888 |
| | | | | | | | | | | | |
Operating expenses | |
|
| |
|
| |
|
| |
|
|
Research and development | |
| 9,871,761 | |
| 7,950,488 | |
| 36,267,116 | |
| 26,540,959 |
General and administrative | |
| 4,106,385 | |
| 3,148,637 | |
| 15,606,529 | |
| 8,271,998 |
Amortization of intangible asset | | | 7,317 | | | — | | | 30,053 | | | — |
Total operating expenses | |
| 13,985,463 | |
| 11,099,125 | |
| 51,903,698 | |
| 34,812,957 |
Loss from operations | |
| (13,985,007) | |
| (11,115,755) | |
| (51,744,868) | |
| (33,886,069) |
| | | | | | | | | | | | |
Other income (expense) | |
|
| |
|
| |
|
| |
|
|
Interest income | |
| 516,167 | |
| 142,885 | |
| 1,014,456 | |
| 169,899 |
Other income (expense) | | | 223,278 | | | (118,974) | | | 216,844 | | | (127,063) |
Loss before income taxes | | | (13,245,562) | | | (11,091,844) | | | (50,513,568) | | | (33,843,233) |
Income tax benefit | | | — | | | 307,485 | | | — | | | 307,485 |
Net loss | | $ | (13,245,562) | | $ | (10,784,359) | | $ | (50,513,568) | | $ | (33,535,748) |
| | | | | | | | | | | | |
Net loss per share attributable to common stockholders, basic and diluted | | | (0.50) | | | (0.42) | | | (1.91) | | | (2.46) |
Weighted-average common shares outstanding, basic and diluted | | | 26,406,933 | | | 25,977,246 | | | 26,386,864 | | | 13,612,677 |
| | | | | | | | | | | | |
Other comprehensive loss: | | | | | | | | | | | | |
Unrealized losses from marketable securities | | | 112,353 | | | (44,258) | | | 18,889 | | | (49,009) |
Comprehensive Loss | | $ | (13,133,209) | | $ | (10,828,617) | | $ | (50,494,679) | | $ | (33,584,757) |
IMMUNEERING CORPORATION
CONSOLIDATED BALANCE SHEETS
(Unaudited)
|
| December 31, 2022 |
| December 31, 2021 | ||
| | | | | | |
Assets |
| |
|
| |
|
Current assets: |
| |
|
| |
|
Cash and cash equivalents | | $ | 72,636,886 | | $ | 74,888,145 |
Marketable securities, current | | | 32,887,970 | | | 74,311,203 |
Accounts receivable | |
| 12,417 | |
| 246,040 |
Prepaids and other current assets | |
| 3,209,536 | |
| 2,888,608 |
Total current assets | |
| 108,746,809 | |
| 152,333,996 |
| | | | | | |
Marketable securities, non-current | | | — | | | 996,560 |
Property and equipment, net | |
| 1,369,608 | |
| 807,223 |
Goodwill | | | 6,690,431 | | | 6,701,726 |
Intangible asset | | | 408,947 | | | 439,000 |
Right-of-use assets, net | |
| 4,407,785 | |
| 5,324,198 |
Other assets | |
| 743,703 | |
| 102,129 |
Total assets | | $ | 122,367,283 | | $ | 166,704,832 |
| | | | | | |
Liabilities, convertible preferred stock and stockholders' equity | |
|
| |
|
|
Current liabilities: | |
|
| |
|
|
Accounts payable | | $ | 3,154,557 | | $ | 1,394,340 |
Accrued expenses | |
| 4,500,993 | |
| 3,965,447 |
Other liabilities, current | | | 19,796 | | | — |
Lease liabilities, current | |
| 378,723 | |
| 274,039 |
Total current liabilities | |
| 8,054,069 | |
| 5,633,826 |
| | | | | | |
Long-term liabilities: | |
|
| |
|
|
Lease liabilities, non-current | |
| 4,462,959 | |
| 5,090,897 |
Total liabilities | |
| 12,517,028 | |
| 10,724,723 |
Commitments and contingencies (Note 13) | |
|
| |
|
|
Stockholders’ equity: | |
|
| |
|
|
Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2022 and December 31, 2021; No shares issued or outstanding | | | — | |
| — |
Class A common stock, $0.001 par value, 200,000,000 shares authorized at December 31, 2022 and December 31, 2021; 26,418,732 and 26,320,199 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively | |
| 26,419 | |
| 26,320 |
Class B common stock, $0.001 par value, 20,000,000 shares authorized at December 31, 2022 and December 31, 2021; 0 shares issued and outstanding at December 31, 2022 and December 31, 2021 | |
| — | |
| — |
Additional paid-in capital | |
| 219,640,912 | |
| 215,276,186 |
Accumulated other comprehensive loss | | | (30,120) | | | (49,009) |
Accumulated deficit | |
| (109,786,956) | |
| (59,273,388) |
Total stockholders' equity | |
| 109,850,255 | |
| 155,980,109 |
Total liabilities, convertible preferred stock and stockholders' equity | | $ | 122,367,283 | | $ | 166,704,832 |
| Building a Universal-RAS Franchise Nasdaq: IMRX With the potential to benefit more than 1.5 million cancer MARCH 2023 patients |
| 2 2023 Corporate Presentation This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding Immuneering Corporation’s (the “Company”) plans to develop, manufacture and commercialize its product candidates, the timing or outcome (including interim results) of the Company’s ongoing or planned clinical trials for IMM-1-104, including our Phase 1/2a clinical trial, any of the Company’s other pipeline product candidates and any future product candidates, the clinical utility of the Company’s product candidates and treatment potential, the ongoing impact of the COVID-19 pandemic on the Company’s business and operations, including manufacturing, research and development, clinical trials and employees, the Company’s cash needs and availability, projected cash runway and current operating plans, and the plans and objectives of management for future operations. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, without limitation: our ability to successfully complete our Phase 1/2a clinical trial, or any planned clinical trials and for those trials to produce positive results, our estimates of the number of patients who suffer from the diseases we are targeting and benefit from the medicines we are developing, and the number of patients that may enroll in our clinical trials; our ability to file INDs in the future; the commercializing of our product candidates, if approved; the timing of the initiation, progress and potential results of our ongoing and planned preclinical studies and clinical trials and our research programs, including our Phase 1/2a clinical trial; our ability to advance additional product candidates into, and successfully complete, preclinical studies and clinical trials with those additional product candidates; the timing or likelihood of regulatory filings and approvals; our product development and marketing strategy; the negative impacts of the COVID-19 pandemic; our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; future strategic arrangements and/or collaborations and the potential benefits of such arrangements; our estimates regarding expenses, future revenue, capital requirements and needs for financing and our ability to obtain capital; the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; our ability to retain the continued service of our key personnel and to identify, hire and retain additional qualified professionals; the implementation of our business model, strategic plans for our business and product candidates; our compliance with laws, the scope of protection we are able to establish and maintain for intellectual property rights, product candidates and our pipeline; our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; the pricing, coverage and reimbursement of our product candidates, if approved; and developments relating to our competitors and our industry, including competing product candidates and therapies. These and other important factors discussed under the caption “Risk factors” in the Company’s most recent periodic filing with the Securities and Exchange Commission (SEC) and its other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this presentation. Any such forward-looking statements represent management’s estimates as of the date of this presentation. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this presentation. FORWARD-LOOKING STATEMENTS AND OTHER DISCLAIMERS |
| “Our approach is different.” • Targeting large Universal-RAS patient population (1.5M) versus more limited approaches. • Monotherapy vs combination therapy potential • Deep cyclic inhibition achieved briefly but forcefully, due to combination of: • Manyfold higher CMAX • and short half life • Approach designed to spare healthy cells and potential to limit adaptive resistance. 3 2023 Corporate Presentation “IMM-1-104 demonstrates Universal-RAS potential.” “2023 is shaping up to be our breakout year.” Investment Summary • First patient dosed in Phase 1/2a trial of lead asset IMM-1-104 in November 2022. • Patient enrollment ongoing; investigator enthusiasm high. • Broad inclusion criteria facilitates rapid trial enrollment. • Upcoming data readouts, beginning mid-2023 • Cash runway projected into Q4 2024 • Robust preclinical activity observed in: • Pancreatic Cancer (KRASG12C & G12V) • NSCLC (KRASG12S) • CRC (KRASG12D) • Melanoma (NRASQ61R) • And others • Hypothesis for IMM-1-104 from proprietary model. • Validated using proprietary bioinformatics & 3D tumor growth assays |
| 4 2023 Corporate Presentation IMM-1-104’s Potential … Universal-RAS NRAS (14.12%) Targeted KRASG12C • Based on 27,461 out of 148,268 (18.5%) patients with RAS-mutated tumors in the AACR GENIE database, v13.0 • Percentage of overall mutation shown under RAS paralogue • Select mutation percentages within KRAS are shown HRAS (2.78%) KRAS (83.10%) |
| 5 2023 Corporate Presentation MoA Target Engagement Prevent MAPK -pathway bypass events GOAL: Expanded activity into RAS mutant setting Near -Zero Drug Trough Short plasma half -life GOAL: Improve tolerability and limit adaptive resistance: every day is a drug holiday Dramatic PK CMAX Pulse Many fold higher drug free fraction CMAX than other MEK inhibitors GOAL: Break Tumor Addiction 1. 2. Deep, Cyclic Inhibition 3. Plasma PK – 5 Day Comparison Days Conceptual illustration of deep cyclic inhibition |
| PROGRAM INDICATION DISCOVERY IND-ENABLING PHASE 1 PHASE 2 PHASE 3 MILESTONE IMM-1-104 Universal-RAS Phase 1/2a Trial Enrolling; initial PK and safety data expected mid-2023 IMM-6-415 Universal-MAPK IND filing in Q4 2023 Multiple additional programs in discovery phase Development Pipeline 6 Cash, cash equivalents and marketable securities of $105.5M as of December 31, 2022 expected to fund operations into Q4 2024 6 2023 Corporate Presentation Wholly Owned Product Portfolio Differentiated by Indication and Half-life Once Daily (QD) Twice Daily (BID) |
| IMM-1-104 |
| 8 2023 Corporate Presentation IMM-1-104 ➢ Potential for Universal-RAS Activity ➢ Deep Cyclic Inhibition; Once-Daily Oral Dosing ➢ Short plasma half-life to minimize drug trough ➢ Initially being developed as Monotherapy ➢ Designed to Resist CRAF-bypass in RAS mutant tumors • Phase 1 recruiting all-comer RAS solid tumors: NCT05585320 • First patient dosed November 2022 • Robust pre-clinical activity observed in 6 different animal models; well-tolerated (median body weight loss of less than 3-6% at top doses) |
| IMM-1-104 Demonstrates Universal-RAS Potential 9 2023 Corporate Presentation Humanized 3D-TGA RAS, RAF mutation Response # Non-Response # NRAS G12 2 0 NRAS G13 1 0 NRAS Q61 17 2 KRAS A146 1 0 KRAS G12 36 8 KRAS G13 ^ 3 1 KRAS Q61 3 0 HRAS G13 * 1 0 BRAF (Class I or II) 21 4 Total 85 (85.0%) 15 (15.0%) ^ 1 model also bearing KRAS Q61 /// * 1 model also bearing NRAS Q61 RAS, RAF mutation Response # Non-Response # Not Present 17 15 Total 17 (53.1%) 15 (46.9%) Response to IMM-1-104 based on 3D-TGA and other preclinical modeling. Parallel translational efforts are focused on projecting patient-aligned molecular profiles or ‘Targetability’. # Models tested in 3D-TGA were assigned responsive if dose response IC50 < 1uM (sensitive) or IC50 ≥ 1 with >25% reduction at 10uM (intermediate), and non-responsive otherwise (resistant) † Select 3D-TGA models: (1.) Pancreatic MIA PaCa-2 (sensitive/responsive), (2.) Pancreatic Capan-2 (intermediate/responsive), (3.) Melanoma SK-MEL-2 (sensitive/responsive), (4.) Lung A549 (intermediate/responsive) Tissue Response # Non-Response # Pancreatic † 17 2 Melanoma † 22 0 Lung † 19 6 CRC 20 5 Thyroid 6 1 Soft Tissue 2 1 Breast 2 6 Gastric 4 2 Ovary 3 2 Prostate 1 2 Fibrosarcoma 1 0 Liver 4 2 Neuroblastoma 1 1 Total 102 (77.3%) 30 (22.7%) Kolitz, et al. 2023 AACR: Targeting RAS Philadelphia, PA 132 Tumor Models 75 = RAS Mutant |
| IMM-1-104 Demonstrates Universal-RAS Potential ELN: PJK03-0013PK 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 0 250 500 750 1000 1250 1500 1750 2000 2250 2500 2750 3000 3250 3500 Time (days) Tu m o r v olu m e (M e dia n ± Q u artile; m m 3 ) **Data: TV (mm3) - 100 + 150 mpk - IMM-1-104 MEDIAN Vehicle 0 mg/kg BID po MEDIAN 150 mg/kg IMM-01-00104 BID po MEDIAN 100 mg/kg IMM-01-00104 BID po IMM-1-104 (TGI = 76%) (TGI = 90%) 0 3 6 9 12 15 18 21 0 50 100 150 200 250 300 350 400 450 500 550 600 650 700 Time (days) Tumor volume (Median ± Quartile; mm3 ) Copy of __Pres Data: TV (mm3) - Dose Range - IMM-01-00104 MEDIAN: 0 mg/kg Vehicle QD po : 0 mg/kg Vehicle BID po MEDIAN: 0 mg/kg Vehicle QD po : 100 mg/kg IMM-1-104 BID po MEDIAN: 0 mg/kg Vehicle QD po : 150 mg/kg IMM-1-104 BID po MIA PaCa-2 N=12 TGI Day21 = 122% TGI Day21 = 108% KRASG12C PANC 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 0 250 500 750 1000 1250 1500 1750 2000 2250 2500 Time (days) Tu m o r v olu m e (M e dia n ± Q u artile; m m 3 ) **Data: TV (mm3) - 100 + 150 mpk - IMM-1-104 MEDIAN Vehicle 0 mg/kg BID po MEDIAN 150 mg/kg IMM-01-00104 BID po MEDIAN 100 mg/kg IMM-01-00104 BID po A-549 N=12 TGI Day28 = 95% TGI Day28 = 91% KRASG12S NSCLC 0 1 2 3 4 5 6 7 8 9 10 0 100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 Time (days) Tumor Volume (Median ± quartile.; mm3 ) Copy of *Data: TV (mm3) - IMM-1-104 - 100 and 150 doses Vehicle 0 mg/kg BID po 100 mg/kg BID po IMM-1-104 150 mg/kg BID po IMM-1-104 Colon-26 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 0 250 500 750 1000 1250 1500 1750 2000 2250 2500 Time (days) Tu m o r v olu m e (M e dia n ± Q u artile; m m 3 ) **Data: TV (mm3) - 100 + 150 mpk - IMM-1-104 MEDIAN Vehicle 0 mg/kg BID po MEDIAN 150 mg/kg IMM-01-00104 BID po MEDIAN 100 mg/kg IMM-01-00104 BID po N=8 TGI Day10 = 108% TGI Day10 = 84% KRASG12D CRC SK-MEL-2 N=12 0 3 6 9 12 15 18 21 0 100 200 300 400 500 600 700 800 900 1000 Time (days) Tumor volume (Median ± Quartile; mm3 ) Mic Drop Panel: TV (mm3) - DR IMM-1-104 MEDIAN: 0 mg/kg Vehicle BID po MEDIAN: 100 mg/kg IMM-1-104 BID po MEDIAN: 125 mg/kg IMM-1-104 BID po MEDIAN: 150 mg/kg IMM-1-104 BID po TGI Day21 = 100% TGI Day21 = 75% TGI Day21 = 91% NRASQ61R MEL CRC = colorectal cancer; NSCLC = non-small cell lung cancer; MEL = melanoma; PANC = pancreatic cancer Maximum Effective Dose Range in Mice (plasma t1/2 = 1.3 hours) is 100 mg/kg to 150 mg/kg BID po Tumor Growth Inhibition (TGI) % = [1 – (Ti – T0)/(Ci – C0)]x100 ; T = treatment groups ; C = control groups *Well-tolerated at top doses with no more than 3-6% median body weight loss (BWL) **Capan-2 PANC model, as reported at ASCO 2022 (0% TGI for sotorasib and adagrasib at top doses) Well Tolerated: Median Body Weight Loss ≤ 3-6%* of baseline at top doses 10 2023 Corporate Presentation ELN: PJK03-0013PK 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 0 250 500 750 1000 1250 1500 1750 2000 2250 2500 2750 3000 3250 3500 Time (days) Tu m or v olu m e (M e dia n ± Q u artile; m m3 ) **Data: TV (mm3) - 100 + 150 mpk - IMM-1-104 MEDIAN Vehicle 0 mg/kg BID po MEDIAN 150 mg/kg IMM-01-00104 BID po MEDIAN 100 mg/kg IMM-01-00104 BID po IMM-1-104 (TGI = 76%) (TGI = 90%) N=12 KRASG12V PANC 0 3 6 9 12 15 18 21 0 50 100 150 200 250 300 350 400 450 500 550 600 650 Time (days) Tumor volume (Median ± Quartile; mm3 ) Copy of BID Data: TV (mm3) - IMM-1-104 MEDIAN: 0 mg/kg Vehicle BID po MEDIAN: 100 mg/kg IMM-1-104 BID po MEDIAN: 150 mg/kg IMM-1-104 BID po CAPAN-2 (KRAS-G12V) Capan-2 TGI Day21 = 84% TGI Day21 = 61% |
| Pancreatic: Head-to-Head Comparison of IMM-1-104 +/- Sotorasib in a KRAS-G12C Pancreatic Tumor Model MIA PaCa-2 (KRASG12C) Pancreatic Xenograft Tumor Model in Athymic Nude Mice Sotorasib was commercially purchased Tumor Growth Inhibition (TGI) % = [1 – (Ti – T0 )/(Ci – C0 )]x100%; Expanded TGI formula vs. previous 1-[T/C]x100% method IMM-1-104 as compared to sotorasib demonstrated tumor regression, both with insignificant BWL 11 2023 Corporate Presentation (N=12, per group) 0 3 6 9 12 15 18 21 0 50 100 150 200 250 300 350 400 450 500 550 600 650 700 750 Time (days) Tumor volume (Median ± Interquartile; mm3 ) Copy of __Pres Data: TV (mm3) - 100 - AMG-510 MEDIAN: 0 mg/kg Vehicle QD po : 0 mg/kg Vehicle BID po MEDIAN: 100 mg/kg AMG-510 QD po : 0 mg/kg Vehicle BID po Median Body Weight Loss 0% of Baseline 100 mg/kg Shown (N=12, per group) 0 3 6 9 12 15 18 21 0 50 100 150 200 250 300 350 400 450 500 550 600 650 700 750 Time (days) Tumor volume (Median ± Interquartile; mm3 ) Copy of __Pres Data: TV (mm3) - 150 mg - IMM-01-00104 MEDIAN: 0 mg/kg Vehicle QD po : 0 mg/kg Vehicle BID po MEDIAN: 0 mg/kg Vehicle QD po : 150 mg/kg IMM-1-104 BID po 0 3 6 9 12 15 18 21 0 50 100 150 200 250 300 350 400 450 500 550 600 650 700 750 Time (days) T u m o r v olu m e (M e dia n ± Inte r q u a rtile; m m 3 ) Copy of __Pres Data: TV (mm3) - 150 mg - IMM-01-00104 MEDIAN: 0 mg/kg Vehicle QD po : 0 mg/kg Vehicle BID po MEDIAN: 0 mg/kg Vehicle QD po : 150 mg/kg IMM-1-104 BID po (N=12, per group) Median Body Weight Loss < 1.8% of Baseline 150 mg/kg Shown (N=12, per group) 0 3 6 9 12 15 18 21 0 50 100 150 200 250 300 350 400 450 500 550 600 650 700 750 Time (days) Tumor volume (Median ± Interquartile; mm3 ) __Data: TV (mm3) - ALL combinations together 0 mg/kg Vehcile QD po : 0 mg/kg Vehicle BID po 30 mg/kg AMG-510 QD po : 50 mg/kg IMM-1-104 BID po 30 mg/kg AMG-510 QD po : 100 mg/kg IMM-1-104 BID po 30 mg/kg AMG-510 QD po : 150 mg/kg IMM-1-104 BID po 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 0 200 400 600 800 1000 1200 1400 1600 1800 Time (days) Tumor volume (Median ± Interquartile; mm3 ) __Pres Data: TV (mm3) - Individual - 30 mpk AMG-510 + 150 mpk IMM-1-104 0 mg/kg Vehicle QD po : 0 mg/kg Vehicle BID po 0 mg/kg Vehicle QD po : 150 mg/kg IMM-1-104 BID po 30 mg/kg sotorasib QD po : 0 mg/kg Vehicle BID po 30 mg/kg sotorasib QD po : 150 mg/kg IMM-1-104 BID po MEDIAN: 0 mg/kg Vehicle QD po : 0 mg/kg Vehicle BID po MEDIAN: 0 mg/kg Vehicle QD po : 150 mg/kg IMM-1-104 BID po MEDIAN: 30 mg/kg sotorasib QD po : 0 mg/kg Vehicle BID po MEDIAN: 30 mg/kg sotorasib QD po : 150 mg/kg IMM-1-104 BID po IMM-1-104 : Sotorasib 0 : 0 0 : 30 150 : 0 150 : 30 NO TREATMENT + 21 Days 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 0 200 400 600 800 1000 1200 1400 1600 1800 Time (days) Tumor volume (Median ± Interquartile; m m3 ) __Pres Data: TV (mm3) - Individual - 30 mpk AMG-510 + 150 mpk IMM-1-104 0 mg/kg Vehicle QD po : 0 mg/kg Vehicle BID po 0 mg/kg Vehicle QD po : 150 mg/kg IMM-1-104 BID po 30 mg/kg sotorasib QD po : 0 mg/kg Vehicle BID po 30 mg/kg sotorasib QD po : 150 mg/kg IMM-1-104 BID po MEDIAN: 0 mg/kg Vehicle QD po : 0 mg/kg Vehicle BID po MEDIAN: 0 mg/kg Vehicle QD po : 150 mg/kg IMM-1-104 BID po MEDIAN: 30 mg/kg sotorasib QD po : 0 mg/kg Vehicle BID po MEDIAN: 30 mg/kg sotorasib QD po : 150 mg/kg IMM-1-104 BID po 0 3 6 9 12 15 18 21 0 50 100 150 200 250 300 350 400 450 500 550 600 650 700 750 Time (days) Tumor volume (Median ± Interquartile; m m3 ) __Data: TV (mm3) - ALL combinations together 0 mg/kg Vehicle QD po : 0 mg/kg Vehicle BID po 30 mg/kg sotorasib QD po : 50 mg/kg IMM-1-104 BID po 30 mg/kg sotorasib QD po : 100 mg/kg IMM-1-104 BID po 30 mg/kg sotorasib QD po : 150 mg/kg IMM-1-104 BID po TREATMENT 21 Days Median Body Weight < 1.0% of baseline at top dose combination IMM-1-104 : Sotorasib 50 : 30 100 : 30 150 : 30 Sotorasib 10-30-100 mg/kg QD p.o.) IMM-1-104 + Sotorasib (50-100-150 mg/kg BID + 30 mg/kg QD) IMM-1-104 (50-100-150 mg/kg BID p.o.) IMM-1-104 + Sotorasib (150 mg/kg BID + 30 mg/kg QD) 0 3 6 9 12 15 18 21 0 50 100 150 200 250 300 350 400 450 500 550 600 650 700 750 Time (days) T u m or v olu m e (M e dia n ± Interq u artile; m m 3 ) __Pres Data: TV (mm3) - 100 - AMG-510 100 mg/kg AMG-510 QD po : 0 mg/kg Vehicle BID po MEDIAN: 0 mg/kg Vehicle QD po : 0 mg/kg Vehicle BID po MEDIAN: 100 mg/kg sotorasib QD po : 0 mg/kg Vehicle BID po TGI TGI = 127% TGI = 122% top-combo = 131% |
| Pancreatic: Head-to-Head Comparison of IMM-1-104 vs. Sotorasib and Adagrasib in a KRAS-G12V Pancreatic Tumor Model IMM-1-104 demonstrated tumor regression as compared to sotorasib or adagrasib, with insignificant BWL 12 2023 Corporate Presentation Adagrasib (30, 100 mg/kg QD p.o.) IMM-1-104 (100, 150 mg/kg BID p.o.) Sotorasib (30, 100 mg/kg QD p.o.) 0 3 6 9 12 15 18 21 0 50 100 150 200 250 300 350 400 450 500 550 600 650 700 750 Time (days) Tumor volume (Median ± Quartile; mm3 ) Copy of BID Data: TV (mm3) - IMM-1-104 MEDIAN: 0 mg/kg Vehicle BID po MEDIAN: 100 mg/kg IMM-1-104 BID po MEDIAN: 150 mg/kg IMM-1-104 BID po CAPAN-2 (KRAS-G12V) 0 3 6 9 12 15 18 21 0 50 100 150 200 250 300 350 400 450 500 550 600 650 700 750 Time (days) T u m or v olu m e (M e dia n ± Q u artile; m m 3 ) Copy of BID Data: TV (mm3) - IMM-1-104 MEDIAN: 0 mg/kg Vehicle BID po MEDIAN: 100 mg/kg IMM-1-104 BID po MEDIAN: 150 mg/kg IMM-1-104 BID po CAPAN-2 (KRAS-G12V) 0 3 6 9 12 15 18 21 0 50 100 150 200 250 300 350 400 450 500 550 600 650 700 750 Time (days) Tumor volume (Median ± Quartile; mm3 ) QD Data: TV (mm3) - MRTX845 Adagrasib MEDIAN: 0 mg/kg Vehicle QD po MEDIAN: 30 mg/kg adagrasib QD po MEDIAN: 100 mg/kg adagrasib QD po CAPAN-2 (KRAS-G12V) 0 3 6 9 12 15 18 21 0 50 100 150 200 250 300 350 400 450 500 550 600 650 700 750 Time (days) T u m o r v olu m e (M e dia n ± Q u a rtile; m m 3 ) QD Data: TV (mm3) - MRTX845 Adagrasib MEDIAN: 0 mg/kg Vehicle QD po MEDIAN: 30 mg/kg adagrasib QD po MEDIAN: 100 mg/kg adagrasib QD po CAPAN-2 (KRAS-G12V) 0 3 6 9 12 15 18 21 0 50 100 150 200 250 300 350 400 450 500 550 600 650 700 750 Time (days) Tumor volume (Median ± Quartile; mm3 ) QD Data: TV (mm3) - AMG-510 Sotorasib MEDIAN: 0 mg/kg Vehicle QD po MEDIAN: 30 mg/kg sotorasib QD po MEDIAN: 100 mg/kg sotorasib QD po CAPAN-2 (KRAS-G12V) (N=12, per group) (N=12, per group) (N=12, per group) 0 3 6 9 12 15 18 21 0 50 100 150 200 250 300 350 400 450 500 550 600 650 700 750 Time (days) T u m o r v o ul m e (M e dia n ± Q u a rtile; m m 3 ) QD Data: TV (mm3) - AMG-510 Sotorasib MEDIAN: 0 mg/kg Vehicle QD po MEDIAN: 30 mg/kg sotorasib QD po MEDIAN: 100 mg/kg sotorasib QD po CAPAN-2 (KRAS-G12V) Capan-2 (KRASG12V) Pancreatic Xenograft Tumor Model in Athymic Nude Mice Sotorasib and adagrasib were commercially purchased Tumor Growth Inhibition (TGI) % = [1 – (Ti – T0 )/(Ci – C0 )]x100%; Expanded TGI formula vs. previous 1-[T/C]x100% method Median Body Weight Loss 0% of Baseline Median Body Weight Loss 0% of Baseline Median Body Weight Loss <5.8% of Baseline |
| Dummer, et al 2017 Lancet S1470-2045 (17) 30180-8 2.8 months 1.5 months 11.0 months 10.1 months Binimetinib Dacarbazine Hazard Ratio Progression Free Survival Overall Survival 0.62 1.00 NRAS Status Binimetinib Dacarbazine N = 269 N = 133 Q61K 100 (37%) 51 (38%) Q61L 32 (12%) 17 (13%) Q61R 137 (51%) 64 (48%) Wildtype 0 1 (1%) Serious Adverse Events (34% binimetinib vs. 22% dacarbazine) Overall Response Rate (ORR: 15% binimetinib vs. 7% dacarbazine) Melanoma: Phase 3 NEMO Study: Binimetinib vs. Dacarbazine (NRASmut Melanoma) Summary of phase 3 data from the NEMO study as reported in Lancet (c.2017) 13 2:1 2023 Corporate Presentation |
| Melanoma: Head-to-Head NRAS-Q61R Melanoma Xenograft Study: Binimetinib vs. IMM-1-104 in SK-MEL-2 IMM-1-104 as compared to binimetinib monotherapy demonstrated greater tumor growth inhibition (TGI) SK-MEL-2 (NRAS-Q61R) Melanoma Xenograft Tumor Model in Athymic Nude Mice CRAF-bypass IMM-1-104 (100-125-150 mg/kg BID p.o.) Binimetinib (3-10-30 mg/kg BID p.o.) 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 0 100 200 300 400 500 600 700 800 900 1000 Time (days) Tumor volume (Median ± Interquartile; mm3 ) SK-MEL-2 (NRAS-mutant MEL) - IMM-1-104 MEDIAN: 0 mg/kg Vehicle BID po MEDIAN: 100 mg/kg IMM-1-104 BID po MEDIAN: 125 mg/kg IMM-1-104 BID po MEDIAN: 150 mg/kg IMM-1-104 BID po 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 0 100 200 300 400 500 600 700 800 900 1000 Time (days) Tumor volume (Median ± Interquartile; mm3 ) SK-MEL-2 (NRAS-mutant MEL) - Binimetinib MEDIAN: 0 mg/kg Vehicle BID po MEDIAN: 3 mg/kg Binimetinib BID po MEDIAN: 10 mg/kg Binimetinib BID po MEDIAN: 30 mg/kg Binimetinib BID po 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 0 100 200 300 400 500 600 700 800 900 1000 Time (days) Tum or volume (Median ± Interquartile; m m3 ) SK-MEL-2 (NRAS-mutant MEL) - IMM-1-104 MEDIAN: 0 mg/kg Vehicle BID po MEDIAN: 100 mg/kg IMM-1-104 BID po MEDIAN: 125 mg/kg IMM-1-104 BID po MEDIAN: 150 mg/kg IMM-1-104 BID po 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 0 100 200 300 400 500 600 700 800 900 1000 Time (days) Tum or volume (Median ± Interquartile; m m3 ) SK-MEL-2 (NRAS-mutant MEL) - Binimetinib MEDIAN: 0 mg/kg Vehicle BID po MEDIAN: 3 mg/kg Binimetinib BID po MEDIAN: 10 mg/kg Binimetinib BID po MEDIAN: 30 mg/kg Binimetinib BID po N=12, per group N=12, per group TGI = 100% TGI = 91% TGI = 75% TGI = 35% 14 2023 Corporate Presentation Binimetinib was commercially purchased |
| CRC: Head-to-Head Comparison of IMM-1-104 Against Selumetinib and Binimetinib in a KRAS-G12D CRC Syngeneic Mouse Tumor Model 0 3 6 9 12 15 18 21 24 27 0 250 500 750 1000 1250 1500 1750 2000 2250 2500 Time (days) Tumor volume (Median ± Quartile; mm3 ) Data: TV (mm3) - Selumetinib - 50 only Vehicle 0 mg/kg BID po 50 mg/kg BID po Selumetinib 50 mg/kg BID po Selumetinib - Individual 0 3 6 9 12 15 18 21 24 27 0 250 500 750 1000 1250 1500 1750 2000 2250 2500 Time (days) Tumor volume (Median ± Quartile; mm3 ) Data: TV (mm3) - IMM-1-104 - Spider Plot - 150 only Vehicle 0 mg/kg BID po 150 mg/kg BID po IMM-1-104 150 mg/kg BID po IMM-1-104 - Individual 0 3 6 9 12 15 18 21 24 27 0 250 500 750 1000 1250 1500 1750 2000 2250 2500 Time (days) Tumor volume (Median ± Quartile; mm3 ) Data: TV (mm3) - Binimetinib - 30 dose only Vehicle 0 mg/kg BID po 30 mg/kg BID po Binimetinib 30 mg/kg BID po Binimetinib - Individual Colon-26 (KRAS-G12D) Syngeneic Colorectal Tumor Model in Balb/c Mice Selumetinib and binimetinib were commercially purchased Tumor Growth Inhibition (TGI) % = [1 – (Ti – T0)/(Ci – C0)]x100%; Expanded TGI formula vs. previous 1-[T/C]x100% method IMM-1-104 demonstrated greater tumor growth inhibition (TGI), lower body weight loss (BWL) and greater durability via reductions in tumor volume (TV) IMM-1-104 (Clinical) Binimetinib (FDA approved) Selumetinib (FDA approved) 15 N=8, per group N=8, per group N=8, per group 2023 Corporate Presentation |
| IMM-1-104: Phase 1/2 Clinical Trial Plan * Solid tumor, all comer with evidence of RAS mutation ** Simon 2-Stage Design. Proposed tumor types may change based upon preclinical PGx studies and clinical function review Study 1 First Time in Humans RP2D May expand tolerated dose cohorts for a max of 42 patients treated in Phase 1 • RAS mutated Melanoma (~40 pts) • RAS Mutated NSCLC-Adeno (~40 pts) • RAS Mutated, APC wt CRC (~40 pts) • RAS Mutated Pancreatic (PAAD) (~40 pts) • MTD = Maximum Tolerated Dose; • RP2D = Recommended Phase 2 Dose; • PGx = Pharmacogenomics IND cleared; First patient dosed on Nov 21, 2022 Expansion 2: Expansion 1: Expansion 3 & 4: biomarker stratification Dose Expansion - Phase 2a** Dose Escalation - Phase 1a* 16 2023 Corporate Presentation IMM-1-104 (Dual MEK inhibitor) Bayesian Design (mTPI-2) escalation and dose evaluation in select solid tumor types1 |
| 17 Phase 1 Sites A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors ClinicalTrials.gov Identifier: NCT05585320 MD Anderson Cancer Center › Houston, Texas, United States, 77030 › Principal Investigator: Shubham Pant, MD United States, Texas NEXT Oncology › San Antonio, Texas, United States. 78229 › Principal Investigator: David Sommerhalder, MD MD Weill Cornell Medicine › New York, New York, United States, 10021 › Principal Investigator: Anna Pavlick, DO United States, New York City of Hope › Duarte, California, United States, 91010 › Principal Investigator: Vincent Chung, MD United States, California NEXT Oncology › Fairfax, Virginia, United States, 22031 › Principal Investigator: Alex Spira, MD, PhD United States, Virginia 2023 Corporate Presentation |
| 18 2023 Corporate Presentation Upcoming Potential Milestones Program Milestone Expected Timing IMM-1-104 Initial Phase 1 pharmacokinetic (PK) and safety data Mid-2023 IMM-1-104 Initial Phase 1 pharmacodynamic (PD) modeling data and additional PK and safety data 2H 2023 IMM-1-104 RP2D and Safety data Mid-2024 IMM-1-104 Additional trial updates On a periodic basis IMM-6-415 IND filing 4Q 2023 |
| IMM-6-415 |
| IMM-6-415: Monotherapy Activity in RAF and RAS Mutant Tumors SK-MEL-2 A-375 A-549 Colon-26 KRASG12S NSCLC KRASG12D CRC NRASQ61R MEL BRAFV600E MEL SITC 2022 Presentation: Maximum Effective Dose Range in Mice (plasma t CRC = colorectal cancer; NSCLC = non-small cell lung cancer; MEL = melanoma 1/2 = 0.3 to 0.4 hours): 150-180 mg/kg BID Well Tolerated up to Maximum Monotherapy Effective Dose Range of 150 to 180 mg/kg 20 Model HRAS NRAS BRAF NF1 3D-TGA SK-MEL-2 p .Q61R MM127 p .G13R p .G464E n.t. MM415 p .Q61L n.t. MEL-JUSO p .G13D p .Q61L n.t. SK-MEL-30 p .Q61K n.t. Hs852T p .G12V n.t. MeWo LoF n.t. A375 p .V600E SK-MEL-28 p .V600E 3D-Tumor Growth Assay (3D-TGA) sensitivity (green) SK-MEL-28 BRAFV600E MEL 0 2 4 6 8 10 12 14 16 18 20 22 0 200 400 600 800 1000 1200 1400 1600 Time (days) Tumor volume (Median ± Quartile or Individual; mm3 ) A549 (KRASG12S) 180 mg/kg BID PO MEDIAN: IMM-6-415, 180mg/kg, 10ul/g, p.o., BID × 21 MEDIAN: Vehicle, 0mg/kg, 10ul/g, p.o., BID x 21 IMM-6-415, 180mg/kg, 10ul/g, p.o., BID × 21 N = 12 mice per group ** **** ** P = 0.0015; day 7 **** P < 0.0001; day 10-21 **** **** **** 1104 mm3 197 mm3 138 mm3 2-way ANOVA followed by Tukey for mulitple comparisons 0 1 2 3 4 5 6 7 8 0 100 200 300 400 500 600 700 800 900 Time (days) Tumor volume (Median ± Quartile or Individual mm3 ) Colon 26 (KRASG12D) 175 mg/kg BID PO MEDIAN: Vehicle: 0 mg/kg BID p.o. N = 6 mice per group IMM-6-415: 175 mg/kg BID p.o. MEDIAN: IMM-6-415: 175 mg/kg BID p.o. *** *** *** P = 0.0005; day 4 *** P = 0.0004; day 7 683 mm3 126 mm3 106 mm3 2-way ANOVA followed by Tukey for mulitple comparisons 2023 Corporate Presentation |
| Accelerated Cadence of IMM-6-415 Enhances Activity of Checkpoint Inhibitors Cyclic disruption of MEK improves overall survival with check point inhibitors (SITC 2022) 21 Schedule Dose (mg/kg) Veh ⍺PD-1 (BIW) ⍺CTLA-4 (BIW) IMM-6-415 IMM-6-415 + PD-1 IMM-6-415 + CTLA-4 BID 120 0/12 7/12 11/12 10/12 BID 60 0/12 0/12 8/12 8/12 BID 30 0/12 0/12 5/12 5/12 QD 120 0/12 0/12 7/12 7/12 QD 60 0/12 1/12 4/12 8/12 QD 30 0/12 0/12 6/12 7/12 BIW 10 0/12 4/12 BIW 10 0/12 4/12 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 0 10 20 30 40 50 60 70 80 90 100 Days Probability of Survival BID-Vehicle BIW-Isotype-PD-1 120 mg/kg BID 415 10 mg/kg BIW PD-1 120 mg/kg BID 415 + PD-1 Day 28 PD1 N = 12 mice per group Logrank test for trend, followed by pair-wise Logrank (Mantel-Cox) test ns; p = 0.6358 p = 0.0172 p = <0.0001 p = <0.0001 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 0 10 20 30 40 50 60 70 80 90 100 Days Probability of Survival BID-Vehicle BIW-Isotype-CTLA4 120 mg/kg BID 415 10 mg/kg BIW CTLA4 120 mg/kg BID 415 + CTLA4 Day 28 CTLA4 N = 12 mice per group Logrank test for trend, followed by pair-wise Logrank (Mantel-Cox) test ns; p = 0.1979 p = <0.0001 p = <0.0001 p = <0.0001 • Number of BALB/c mice (out of 12) with tumors through Day 28 with volumes lower than 2,000 mm3 Monotherapy Treated Alive at Day 28 Combination ≥ 3 Advantage Syngeneic CT-26 Model KRASG12D CRC Presented at SITC (Nov. 2022): RAS wild type MC38 IO model ≥3 advantage only observed in IMM-6-415 (120 p.o. BID) + anti-PD-1 2023 Corporate Presentation |
| Corporate |
| • Cash, cash equivalents and marketable securities as of December 31, 2022: $105.5M • Cash runway into Q4 2024 supports: • IMM-1-104: • Multiple data readouts from Phase 1/2a trial • IMM-6-415: • Anticipate IND filing in Q4 2023 • Research in additional oncology programs 23 2023 Corporate Presentation Finance & Intellectual Property Finance Intellectual Property Patents issued/pending: • Pending U.S. and ex-U.S. applications relating to IMM-1-104 • Pending U.S. provisional and PCT applications relating to IMM-6- 415 • Issued U.S. patent and pending application relating to DCT • Pending U.S. applications to Fluency Expected patent expiration: (excluding patent term adjustments, etc.) • IMM-1-104 = 2041 • IMM-6-415 = 2043 • DCT = 2039 • Fluency = 2039 |
| “Our approach is different.” • Targeting large Universal-RAS patient population (1.5M) versus more limited approaches. • Monotherapy vs combination therapy potential • Deep cyclic inhibition achieved briefly but forcefully, due to combination of: • Manyfold higher CMAX and • short half life • Approach designed to spare healthy cells and potential to limit adaptive resistance. 24 2023 Corporate Presentation “IMM-1-104 demonstrates Universal-RAS potential.” “2023 is shaping up to be our breakout year.” Investment Summary • First patient dosed in Phase 1/2a trial of lead asset IMM-1-104 in November 2022. • Patient enrollment ongoing; investigator enthusiasm high. • Broad inclusion criteria facilitates rapid trial enrollment. • Upcoming data readouts, beginning mid-2023 • Cash runway projected into Q4 2024 • Robust preclinical activity observed in: • Pancreatic Cancer (KRASG12C) • NSCLC (KRASG12S) • CRC (KRASG12D) • Melanoma (NRASQ61R) • And others • Hypothesis for IMM-1-104 from proprietary model. • Validated using proprietary bioinformatics & 3D tumor growth assays |
| Appendix Nasdaq: IMRX March 2023 |
| Differentiation Versus Other MEK Inhibitors 1 st Gen Mechanism Potentially Susceptible to CRAF-bypass Potential Short PK Exposure (Improve Tolerability & Durability) Potential Chronic Exposure (Drug Toxicity) 2 nd Gen Mechanism Potentially Resistant to CRAF-bypass BAY-265 VS-6766 Trametinib Cobimetinib Selumetinib Binimetinib Phase 1 IMM-1-104 FDA Registered Clinical Trials Preclinical Immuneering 26 Mirdametinib Clinical Candidate IMM-6-415 3 rd Generation MEKi 2023 Corporate Presentation |
| Our Platform Converts Gene Expression to Counterintuitive Insights Goal: achieve broader activity and better tolerability in RAS and beyond mutant disease Disease Cancellation Disease Amplification Disease Cancellation Disease Amplification 1 st generation MEKi 1 st generation MEKi IMRX Disease Cancelling Technology - US Patent 11,043,305 Unlike first generation MEK inhibitors, IMM-1-104 is designed to prevent RAF- and KSR-mediated activation of MEK (i.e., CRAF-bypass) and displays a short plasma half-life to potentially drive deep cyclic inhibition of the pathway. Data-driven Identification and Optimization of New Medicines to Cancel Cancer Cachexia Presented by Ben Zeskind at the 12th International Conference of Cachexia, Sarcopenia & Muscle Wasting (SCWD) in Berlin, Dec. 6-8, 2019 27 Cancer Cell Growth RAS RAF MEK ERK OFF NF1 ON RAS NANOCLUSTERS P P P P P P P MEK inh RTK 2023 Corporate Presentation |
| Deep Cyclic Inhibition Confirmed Using Transcriptomics Traditional Approach Signaling Dynamics Chronic Suppression → TOXICITY Cyclic Disruption → TOLERABILITY 28 Syngeneic Colon-26 study (18 days BID dosing; tumor RNA) Syngeneic Colon-26 study (18 days BID dosing; tumor RNA) 2023 Corporate Presentation |
| IMM-1-104 is a Dual-MEK Inhibitor Goal deep, cyclic inhibition with ability to prevent MEK-reactivation (improve tolerability and activity) Short plasma half life to minimize drug trough (~ 1 to 2 hours t1/2) Resists CRAF-bypass in RAS mutant tumors (↓ pERK and pMEK) Ideal Dosing Schedule: ≥ 7-8 half lives between doses (BID for < 1.5 hr t1/2; QD for 2 to 3 hr t1/2) IMM-1-104 Mechanism + Half Life 29 Cadence 2023 Corporate Presentation |
| Head-to-Head Comparison of IMM-1-104 Against FDA-Approved MEK Inhibitors: CRAF-Bypass Resistance FDA-Approved MEK inhibitors: Trametinib, Cobimetinib, Binimetinib, Selumetinib commercially purchased 1.00 0.03 0.19 0.17 0.21 0.29 1.00 1.24 6.46 2.96 2.45 0.56 0.01 0.10 1.00 10.00 0.1% DMSO T rametinib Cobimetinib Binimetinib Selumetinib IMM-1-104 p-Protein : total Protein (NormalizedtoDMSO) Drug Dose = 100 nM (2hours exposure;A549) A549KRAS-mut Lung Cancer: pERK and pMEK pERK pMEK CRAF-bypass if > 1.0 Decreased activity for both MEK & ERK A549KRAS-mut Lung Cancer: pERK and pMEK CRAF Bypass > 1.0 30 Cancer Cell Growth RAS RAF MEK ERK OFF NF1 ON RAS NANOCLUSTERS P P P P P P P MEK inh RTK 2023 Corporate Presentation |
| Head-to-Head Comparison of IMM-1-104 Against Binimetinib +/- Encorafenib in KRAS-G12S NSCLC Tumor Model A549 (KRASG12S) NSCLC Xenograft Tumor Model in Athymic Nude Mice Tumor Growth Inhibition (TGI) % = [1 – (Ti – T0 )/(Ci – C0 )]x100%; Expanded TGI formula vs. previous 1-[T/C]x100% method Human Dose Equivalent (HDE) binimetinib = 1-3 mg/kg BID IMM-1-104 as compared to binimetinib monotherapy demonstrated greater tumor growth inhibition (TGI) Binimetinib and encorafenib were commercially purchased IMM-1-104 (150 mg/kg BID p.o.) (N=12, per group) 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 0 250 500 750 1000 1250 1500 1750 2000 2250 2500 Time (days) Tu m o r v olu m e M( e dia n ± Q u artile; m m 3 ) **Data: TV (mm3) - 100 + 150 mpk - IMM-1-104 MEDIAN Vehicle 0 mg/kg BID po MEDIAN 150 mg/kg IMM-01-00104 BID po MEDIAN 100 mg/kg IMM-01-00104 BID po 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 0 250 500 750 1000 1250 1500 1750 2000 2250 2500 Time (days) Tumor volume (Median ± Quartile; mm3 ) **Data: TV (mm3) - 100 + 150 mpk - IMM-1-104 MEDIAN Vehicle 0 mg/kg BID po MEDIAN 150 mg/kg IMM-01-00104 BID po MEDIAN 100 mg/kg IMM-01-00104 BID po IMM-1-104 (TGI = 95%) IMM-1-104 (TGI = 91%) Binimetinib + Encorafenib (10 mg/kg BID + 60 mg/kg QD p.o.) (N=12, per group) Encorafenib (TGI = 41%) …minus 1 → TV limit Binimetinib (TGI = 79%) Bin + Enc (TGI = 62%) 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 0 250 500 750 1000 1250 1500 1750 2000 2250 2500 Time (days) Tumor volume (Median ± Quartile; mm3 ) **Data: TV (mm3) - 60 mpk QD:10 mpk BID - E:B MEDIAN Vehicle 0 mg/kg QD po : Vehicle 0 mg/kg BID po MEDIAN 60 mg/kg Encorafenib QD po : Vehicle 0 mg/kg BID po MEDIAN Vehicle 0 mg/kg QD po : 10 mg/kg Binimetinib BID po MEDIAN 60 mg/kg Encorafenib QD po : 10 mg/kg Binimetinib BID po 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 0 250 500 750 1000 1250 1500 1750 2000 2250 2500 Time (days) Tu m or v olu m e (M e dian ± Quartile; m m3 ) **Data: TV (mm3) - 60 mpk QD:10 mpk BID - E:B MEDIAN Vehicle 0 mg/kg QD po : Vehicle 0 mg/kg BID po MEDIAN 60 mg/kg Encorafenib QD po : Vehicle 0 mg/kg BID po MEDIAN Vehicle 0 mg/kg QD po : 10 mg/kg Binimetinib BID po MEDIAN 60 mg/kg Encorafenib QD po : 10 mg/kg Binimetinib BID po 31 2023 Corporate Presentation |
| Head-to-Head Comparison of IMM-1-104 versus Binimetinib +/- Encorafenib in BRAF-V600E Melanoma Tumor Model A375 (BRAFV600E) Melanoma Xenograft Tumor Model in Athymic Nude Mice Tumor Growth Inhibition (TGI) % = [1 – (Ti – T0 )/(Ci – C0 )]x100%; Expanded TGI formula vs. previous 1-[T/C]x100% method Human Dose Equivalent (HDE) binimetinib 1-3 mg/kg BID IMM-1-104 as compared to binimetinib monotherapy demonstrated greater tumor growth inhibition (TGI) Binimetinib and encorafenib were commercially purchased IMM-1-104 (100 & 150 mg/kg BID p.o.) (N=12, per group) Binimetinib + Encorafenib (10 mg/kg BID + 60 mg/kg QD p.o.) (N=12, per group) IMM-1-104 (TGI = 80%) (TGI = 96%) Encorafenib (TGI = 99%) Binimetinib (TGI = 51%) Bin + Enc (TGI = 107%) Tumor Volume (Median ± quartile; mm3 ) 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 0 250 500 750 1000 1250 1500 1750 2000 2250 2500 2750 3000 3250 3500 Time (days) Tu m o r v olu m e (M e dia n ± Q u artile; m m 3 ) **Data: TV (mm3) - 100 + 150 mpk - IMM-1-104 MEDIAN Vehicle 0 mg/kg BID po MEDIAN 150 mg/kg IMM-01-00104 BID po MEDIAN 100 mg/kg IMM-01-00104 BID po 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 0 250 500 750 1000 1250 1500 1750 2000 2250 2500 Time (days) Tu m or v olu m e (M e dia n ± Q u artile; m m3 ) **Data: TV (mm3) - 60 mpk QD:10 mpk BID - E:B MEDIAN Vehicle 0 mg/kg QD po : Vehicle 0 mg/kg BID po MEDIAN 60 mg/kg Encorafenib QD po : Vehicle 0 mg/kg BID po MEDIAN Vehicle 0 mg/kg QD po : 10 mg/kg Binimetinib BID po MEDIAN 60 mg/kg Encorafenib QD po : 10 mg/kg Binimetinib BID po 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 0 250 500 750 1000 1250 1500 1750 2000 2250 2500 2750 3000 3250 3500 Time (days) Tumor volume (Median ± Quartile; mm3 ) **Data: TV (mm3) - 100 + 150 mpk - IMM-1-104 MEDIAN Vehicle 0 mg/kg BID po MEDIAN 150 mg/kg IMM-01-00104 BID po MEDIAN 100 mg/kg IMM-01-00104 BID po Tumor Volume (Median ± quartile; mm3 ) 32 2023 Corporate Presentation |
| Conclusions (NRAS mutant Melanoma) In the phase 3 NEMO study published in Lancet (c. 2017), binimetinib failed to substantially improve overall survival vs. dacarbazine (11.0 vs. 10.1 months) in NRAS mutant melanoma patients and led to a ~50% increase in serious adverse events (34% vs. 22%). The most common NRAS mutation in the NEMO study was Q61R. We further compared binimetinib vs. IMM-1-104 in vivo using SK-MEL-2 (NRAS-Q61R). Collectively, our data suggest that binimetinib may not effectively control MAPK pathway reactivation in RAS mutant tumors. In contrast, the deep cyclic inhibition combined with a dual-MEK mechanism of action of IMM-1-104 may offer a unique therapeutic advantage over first generation MEK inhibitors in RAS mutant tumors. 33 2023 Corporate Presentation |
| 34 2023 Corporate Presentation RAS Mutation Profiles Within Select Tumor Indications • Based on given tumor type of patients with RAS-mutated tumors in the AACR GENIE database, v13.0 • Each RAS paralogue shown as percent overall RAS mutant tumors within each indication • Presented at 2023 AACR: Targeting RAS. Kolitz, et al. (Philadelphia, PA) Pancreatic Cancer NRAS = 0.34% HRAS = 0.06% KRAS = 99.60% NRAS = 2.67% HRAS = 0.31% KRAS = 97.02% Lung Cancer Melanoma Colorectal Cancer NRAS = 89.14% HRAS = 5.29% KRAS = 5.57% NRAS = 8.25% HRAS = 0.24% KRAS = 91.51% |
| 35 2023 Corporate Presentation I 35 KRAS Mutant Pancreatic (PAAD): Translational Opportunity GENIE cohort v13.0-public The AACR Project GENIE Consortium. AACR Project GENIE: Powering Precision Medicine Through An International Consortium, Cancer Discov. 2017 Aug;7(8):818-831 Sensitive Mixed ↑ Resistance Have Altered KRAS: Biomarker Positive Biomarker Sensitive Profile (80.2% overall) Biomarker Resistant Profile (0.6% overall) † Further Biomarker Stratification Not Required † PANCREATIC Patients Patient mapping with 3D-TGA Translational Step: Assess sensitivity of a panel of cell lines in the 3D-TGA; determine key mutations present in each Bioinformatics Step: How many patients does each cell line represent, based on key mutations present in each |
| 36 2023 Corporate Presentation I 36 NRAS Mutant Melanoma: Translational Opportunity Sensitive Mixed ↑ Resistance Have Altered NRAS: Biomarker Positive Biomarker Sensitive Profile (19% overall) Biomarker Resistant Profile (0.8% overall) † Further Biomarker Stratification Not Required † MELANOMA Patients GENIE cohort v13.0-public The AACR Project GENIE Consortium. AACR Project GENIE: Powering Precision Medicine Through An International Consortium, Cancer Discov. 2017 Aug;7(8):818-831 Patient mapping with 3D-TGA Translational Step: Assess sensitivity of a panel of cell lines in the 3D-TGA; determine key mutations present in each Bioinformatics Step: How many patients does each cell line represent, based on key mutations present in each |
| 37 2023 Corporate Presentation I 37 KRAS Mutant NSCLC (Adeno): Translational Opportunity Have Altered KRAS: Biomarker Positive Biomarker Sensitive Profile (21.5% overall) Biomarker Resistant Profile (Refine Subsets) NSCLC-Ad Patients † Sensitive ↑ Resistance (Further Refine Subsets) † Consider Further Biomarker Stratification GENIE cohort v13.0-public The AACR Project GENIE Consortium. AACR Project GENIE: Powering Precision Medicine Through An International Consortium, Cancer Discov. 2017 Aug;7(8):818-831 Patient mapping with 3D-TGA Translational Step: Assess sensitivity of a panel of cell lines in the 3D-TGA; determine key mutations present in each Bioinformatics Step: How many patients does each cell line represent, based on key mutations present in each |
| 38 2023 Corporate Presentation I 38 KRAS Mutant CRC: Translational Opportunity Have Altered KRAS: Biomarker Positive Biomarker Sensitive Profile (9.3% overall) CRC Biomarker Resistant Profile (Refine Subsets) Patients † Sensitive ↑ Resistance (Further Refine Subsets) † Further Refine Biomarker Stratification GENIE cohort v13.0-public The AACR Project GENIE Consortium. AACR Project GENIE: Powering Precision Medicine Through An International Consortium, Cancer Discov. 2017 Aug;7(8):818-831 Patient mapping with 3D-TGA Translational Step: Assess sensitivity of a panel of cell lines in the 3D-TGA; determine key mutations present in each Bioinformatics Step: How many patients does each cell line represent, based on key mutations present in each |
| Safety • Adverse Events (AEs) 39 2023 Corporate Presentation Dose-limiting Toxicities Recommended Phase 2 Dose • Selection of dose candidate • Number of participants with dose limiting toxicities Phase 1/2a Primary and Secondary Outcomes Phase 1: Primary Outcomes Phase 1/2a: Secondary Outcomes CMAX • Maximum Observed Plasma Concentration TMAX AUC • Area Under Plasma Concentration Time Curve • Time to Reach Maximum Plasma Concentration Phase 2a: Primary Outcome Overall Response Rate • CR or PR based on RECIST 1.1 Phase 2a: Secondary Outcomes Landmark 3-Month Survival Landmark 6-Month Survival Overall Survival (OS) Disease Control Rate Progression Free Survival (PFS) Duration of Response |
